All‐cause death ( · preventing the progression of CKD
It is very uncertain whether metformin changes all‐cause death ( compared with placebo (very low certainty).
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
Metformin showed no clear difference in all‐cause death ( compared with active control (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Low showed no clear difference in all‐cause death compared with standard dose valganciclovir (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Maribavir showed no clear difference in all‐cause death compared with ganciclovir (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
1 finding from 1 review
All‐cause death · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
It is very uncertain whether angiotensin receptor blocker (ARB) changes all‐cause death Median compared with another ARB (very low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (any cause) (median · people with diabetes and kidney disease
1 finding from 1 review